Clinical Trials Logo

Pigmented Villonodular Synovitis clinical trials

View clinical trials related to Pigmented Villonodular Synovitis.

Filter by:

NCT ID: NCT05804045 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Start date: April 27, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: - Whether the Pimicotinib(ABSK021) works well in patients with TGCT. - Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. - Complete the study procedures speficied in the protocol, which is guided by researchers.

NCT ID: NCT05349643 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Start date: January 26, 2023
Phase: Phase 2
Study type: Interventional

AMB-051-07 is an Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension which will enroll approximately 48 adult subjects with TGCT for IA doses over a 24-week dosing period (Part 1) with a Part 2 OLE of 6 treatment and/or observational cycles of 12 weeks each followed by 12 weeks of follow-up.

NCT ID: NCT05059262 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

MOTION
Start date: October 14, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.

NCT ID: NCT04955535 Completed - Clinical trials for Pigmented Villonodular Synovitis

Screening of Specific Genes for Pigmented Villous Nodular Synovitis

Start date: August 3, 2020
Phase:
Study type: Observational

This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions. Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

NCT ID: NCT04952896 Completed - Clinical trials for Rheumatoid Arthritis

Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease

Start date: January 1, 2012
Phase:
Study type: Observational

Through the high-throughput feature extraction of magnetic resonance images, the deep learning prediction model of joint synovial lesions is constructed used for the diagnosis, differential diagnosis and curative effect monitoring of joint synovial lesions.

NCT ID: NCT04938180 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

Start date: September 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of patients with TGCT.

NCT ID: NCT04731675 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Start date: May 25, 2021
Phase: Phase 2
Study type: Interventional

AMB-051-01 is a multicenter study with an adaptive design that will enroll approximately 12 subjects with TGCT of the knee for 12 weeks of multiple-dose, open-label treatment with AMB-05X.

NCT ID: NCT03069469 Active, not recruiting - Clinical trials for Advanced Malignant Neoplasm

Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Start date: February 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label Phase 1/2 study of DCC-3014 in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.

NCT ID: NCT02471716 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

FPA008-002
Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.

NCT ID: NCT02371369 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

ENLIVEN
Start date: May 11, 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good. The main purpose of this study is to gather information about the investigational drug pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS). The study consists of two parts with a follow-up period. In Part 1, eligible study participants will be assigned to receive either pexidartinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Some subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2. Then a protocol amendment was written to allow only pexidartinib patients to continue into Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label pexidartinib. There was also a follow-up period added to Part 2.